| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Nov 9, 2022 | MRK Merck & Co., Inc. | Davis Robert M46 | CEO &President | Sell | 167,613 | $102.44 | $17,169,839.61 | -16.9% | +4.7% | +3.5% | |
| Nov 9, 2022 | JNJ Johnson & Johnson | Wengel Kathryn E61 | EVP, Chief Gsc Officer | Sell | 16,410 | $173.42 | $2,845,772.97 | -18.7% | -4.6% | -14.0% | |
| Nov 9, 2022 | SUPN Supernus Pharmaceuticals, Inc. | Bhatt Padmanabh P.69 | Sr. VP Of Ip, CSO | Sell | 700 | $34.97 | $24,479.91 | -29.9% | +16.7% | -20.0% | |
| Nov 9, 2022 | MRK Merck & Co., Inc. | Oosthuizen Johannes Jacobus | President, U.s. Market | Sell | 1,795 | $103.21 | $185,261.95 | -9.7% | +4.7% | +3.5% | |
| Nov 9, 2022 | BMY Bristol Myers Squibb Co | Powell Ann64 | EVP, Chief Human Resources | Sell | 16,250 | $80.45 | $1,307,312.50 | -32.2% | -6.6% | -36.8% | |
| Nov 9, 2022 | UTHR United Therapeutics Corp | Rothblatt Martine A58 | Chairperson &CEO | Sell | 16,000 | $265.18 | $4,242,835.03 | -26.6% | -3.3% | -16.1% | |
| Nov 8, 2022 | LNTH Lantheus Holdings, Inc. | Heino Mary Anne50 | President &CEO | Sell | 13,150 | $57.21 | $752,365.35 | -0.5% | +5.2% | +11.1% | |
| Nov 8, 2022 | NBIX Neurocrine Biosciences Inc | Cooke Julie59 | Chief Human Resources Officer | Sell | 5,592 | $124.99 | $698,949.11 | -27.0% | -15.2% | -6.9% | |
| Nov 8, 2022 | NBIX Neurocrine Biosciences Inc | Lippoldt Darin60 | Chief Legal Officer | Sell | 5,082 | $125.04 | $635,441.59 | -14.8% | -15.2% | -6.9% | |
| Nov 8, 2022 | DVAX Dynavax Technologies Corp | Novack David F73 | President &COO | Sell | 52,204 | $12.47 | $650,983.88 | -96.2% | -6.6% | +6.7% | |
| Nov 8, 2022 | UTHR United Therapeutics Corp | Olian Judy D.60 | Director | Sell | 600 | $265.09 | $159,054.00 | -6.5% | -2.9% | -14.1% | |
| Nov 7, 2022 | UTHR United Therapeutics Corp | Mesa Nilda47 | Director | Sell | 290 | $268.57 | $77,885.71 | -4.5% | -4.3% | -13.6% | |
| Nov 7, 2022 | TLRY Tilray Brands, Inc. | Kennedy Brendan87 | Director | Sell | 350,000 | $3.78 | $1,322,755.00 | -5.3% | -15.2% | -52.4% | |
| Nov 7, 2022 | MRK Merck & Co., Inc. | Frazier Kenneth C | Executive Chair | Sell | 235,769 | $99.55 | $23,471,432.58 | -9.0% | +4.6% | +6.8% | |
| Nov 7, 2022 | BMY Bristol Myers Squibb Co | Vessey Rupert53 | EVP, Research &Early Dev. | Sell | 45,910 | $78.88 | $3,621,380.80 | -44.6% | -5.9% | -34.0% | |
| Nov 7, 2022 | KNSA Kiniksa Pharmaceuticals International, Plc | Paolini John F.51 | Chief Medical Officer | Sell | 28,357 | $15.18 | $430,459.26 | -43.8% | -6.6% | +8.3% | |
| Nov 7, 2022 | MRK Merck & Co., Inc. | Oosthuizen Johannes Jacobus | President, U.s. Market | Sell | 45,561 | $99.47 | $4,531,980.01 | -71.1% | +4.6% | +6.8% | |
| Nov 7, 2022 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 63,585 | $363.94 | $23,141,043.50 | - | -7.3% | +64.8% | |
| Nov 4, 2022 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 1,336 | $363.77 | $485,996.20 | - | -7.2% | +59.3% | |
| Nov 4, 2022 | JNJ Johnson & Johnson | Mongon Thibaut | Exec VP, Ww Chair, Consumer | Sell | 35,246 | $171.18 | $6,033,304.60 | -26.3% | -2.8% | -11.2% | |
| Nov 4, 2022 | UTHR United Therapeutics Corp | Rothblatt Martine A58 | Chairperson &CEO | Sell | 16,000 | $264.41 | $4,230,502.52 | -18.4% | -2.0% | -15.2% | |
| Nov 4, 2022 | MRK Merck & Co., Inc. | Frazier Kenneth C | Executive Chair | Sell | 470,000 | $98.66 | $46,372,118.02 | -14.1% | +5.0% | +7.1% | |
| Nov 3, 2022 | NBIX Neurocrine Biosciences Inc | Lippoldt Darin60 | Chief Legal Officer | Sell | 4,518 | $125.02 | $564,851.20 | -13.4% | -11.2% | -9.4% | |
| Nov 3, 2022 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 133,948 | $362.08 | $48,499,891.84 | -0.1% | -5.0% | +57.4% | |
| Nov 3, 2022 | UTHR United Therapeutics Corp | Mahon Paul A47 | EVP &General Counsel | Sell | 6,000 | $257.08 | $1,542,494.10 | -3.7% | -2.0% | -15.4% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.